Methadone dose and urine morphine

Area of Science:

• Addiction Medicine
• Pharmacology
• Public Health

Background:

• Methadone maintenance treatment (MMT) is a cornerstone of opioid use disorder management.
• Recommended methadone dosages have evolved over time, with varying clinical practices.
• Understanding factors influencing treatment effectiveness, such as heroin use, is crucial.

Purpose of the Study:

• To investigate the relationship between methadone dosage and urine morphine levels in patients.
• To explore other patient and program variables that may affect illicit opioid use during MMT.

Main Methods:

• Historical and cross-sectional study design within a single methadone maintenance program.
• Analysis of urine drug screens for morphine in relation to methadone dose, duration of treatment, gender, ethnicity, and age.
• Examination of temporal trends in urine morphine positivity and potential associations with program or community changes.

Main Results:

• No significant relationship was found between methadone dose (categorized as <50 mg or ≥50 mg) and urine morphine positivity.
• Patient demographics (gender, ethnicity, age) were not associated with urine morphine levels.
• Longer duration of methadone maintenance (≥3 years) was inversely related to urine morphine positivity, indicating reduced heroin use.

Conclusions:

• Methadone dose appears to be a less critical factor in suppressing heroin use than previously thought.
• Treatment duration is a significant factor associated with decreased illicit opioid use in MMT.
• Programmatic and community-level factors may influence heroin use patterns among patients undergoing methadone maintenance.